[Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma]

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Multiple myeloma (MM) remains a challenge, especially in relapsed/refractory cases, despite advances in novel drug development.
• Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in relapsed/refractory MM but is associated with significant toxicities like cytokine release syndrome and neurotoxicity.
• Natural killer (NK) cells, key players in innate immunity and tumor immunosurveillance, present a promising alternative for MM therapy.

Approach:

• This review explores the potential of CAR-modified NK (CAR-NK) cells as a therapeutic strategy for multiple myeloma.
• It examines the anti-tumor mechanisms, biological characteristics, and dysfunction of NK cells within the MM tumor microenvironment.
• The review synthesizes current basic and clinical research progress on CAR-NK cell therapy for MM.

Key Points:

• CAR-NK cells are being investigated as a safer and potentially more effective alternative to CAR T-cells for MM treatment.
• Multiple specific targets have been identified for CAR-NK cell therapy, demonstrating potent anti-tumor effects in preclinical MM models.
• Understanding NK cell dysfunction in the MM tumor microenvironment is crucial for optimizing CAR-NK cell efficacy.

Conclusions:

• CAR-NK cell therapy represents a promising innovative approach for overcoming the limitations of current MM treatments.
• Further research and clinical trials are warranted to fully establish the therapeutic potential of CAR-NK cells in multiple myeloma.